NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form-2/?id=175415&from=3  CLASS PE ...

Business Transactions - The company completed the sale of its Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion, receiving approximately $3.71 billion in pre-tax cash proceeds at closing [167]. - The company completed the sale of its BioPharma Solutions business for cash proceeds of $3.96 billion, using the after-tax proceeds to repay debt obligations [172]. - The company repaid $3.81 billion of short- and long-term indebtedness during the first nine months of 2025, primarily from the sale of its Kidney Care business [258]. Financial Performance - The company reported a net loss attributable to stockholders of $(46) million, or $(0.09) per diluted share, for the three months ended September 30, 2025, compared to a net income of $140 million, or $0.27 per diluted share, for the same period in 2024 [181]. - For the nine months ended September 30, 2025, the company reported a net income of $171 million, or $0.33 per diluted share, compared to a net loss of $(137) million, or $(0.27) per diluted share, for the same period in 2024 [182]. - The company reported a net loss from continuing operations of $(51) million, or $(0.10) per diluted share, for the three months ended September 30, 2025 [183]. - Total net sales for the three months ended September 30, 2025, were $2,835 million, a 5% increase from $2,699 million in 2024 [186]. - Other revenues for the three months ended September 30, 2025, were $101 million, significantly up from $17 million in the prior year [205]. - Total reportable segment operating income was $433 million in Q3 2025, down from $462 million in Q3 2024 [236]. Segment Performance - In the third quarter of 2025, sales in the United States increased by 3% to $1,544 million, while emerging markets saw a 2% increase to $355 million [186]. - The Medical Products & Therapies segment reported net sales of $1,329 million, a 1% decrease compared to $1,342 million in the same period last year [190]. - Infusion Therapies & Technologies net sales decreased by 4% in the third quarter of 2025, primarily due to lower Novum LVP pump sales [192]. - Advanced Surgery segment net sales increased by 13% in the third quarter of 2025, driven by growth in hemostats and sealants [193]. - Healthcare Systems & Technologies segment net sales increased by 3% in the third quarter of 2025, reaching $773 million [197]. - Pharmaceuticals segment net sales increased by 7% in the third quarter of 2025, totaling $632 million [202]. - Drug Compounding net sales increased by 12% in the third quarter of 2025, driven by improved product mix and increased demand [204]. Expenses and Margins - Gross margin for Q3 2025 was $950 million, representing 33.5% of net sales, down from $1,033 million (38.3%) in Q3 2024, a decrease of 8.0% [209]. - SG&A expenses for Q3 2025 were $708 million, or 25.0% of net sales, compared to $754 million (27.9%) in Q3 2024, a reduction of 6.1% [209]. - R&D expenses for Q3 2025 totaled $118 million, accounting for 4.2% of net sales, down from $129 million (4.8%) in Q3 2024, an 8.5% decrease [209]. - For the nine months ended September 30, 2025, gross margin was $2,802 million (33.9%), down from $3,025 million (38.4%) in the same period of 2024, a decline of 7.4% [210]. - SG&A expenses for the nine months ended September 30, 2025, were $2,129 million (25.7%), compared to $2,206 million (28.0%) in 2024, a decrease of 3.5% [210]. - R&D expenses for the nine months ended September 30, 2025, were $392 million (4.7%), slightly up from $379 million (4.8%) in 2024, an increase of 3.4% [210]. Special Items and Adjustments - The company incurred special items that adversely impacted net income by $401 million, or $0.78 per diluted share, for the three months ended September 30, 2025 [181]. - Special items negatively impacted the gross margin ratio by approximately 5.9 percentage points in Q3 2025 and 6.7 percentage points for the nine months ended September 30, 2025 [211]. - Business optimization charges for Q3 2025 amounted to $38 million, compared to $18 million in Q3 2024, reflecting restructuring efforts post-sale of the Kidney Care segment [212]. - The company expects to incur additional pre-tax costs of approximately $1 million related to ongoing business optimization initiatives [220]. Cash Flow and Debt - Cash flows from operations for the nine months ended September 30, 2025 were $355 million, down from $376 million in the same period of 2024, affected by increased inventory levels [246]. - Cash used in financing activities for the nine months ended September 30, 2025 included debt repayments of $3.51 billion, compared to $827 million in the same period of 2024 [248]. - As of September 30, 2025, the company had $1.73 billion of cash and cash equivalents available to meet operating requirements [258]. - The company had $645 million outstanding under its U.S. Dollar-denominated term loan credit facility, which matures in 2027 [252]. - The Multicurrency Revolver has a maximum capacity of $2.20 billion and matures in 2030, with no borrowings outstanding as of September 30, 2025 [253]. Risks and Challenges - The company experienced challenges in its global supply chain due to Hurricane Helene, which disrupted operations at its North Cove facility [173]. - The company faced adverse impacts from global macroeconomic conditions, including high inflation rates, which have affected costs and customer order patterns [177]. - The company is exposed to foreign exchange risk with revenues generated outside the U.S. in multiple currencies, including Euro, British Pound, and Japanese Yen [273]. - The company faces risks related to the continuity and pricing of acceptable raw materials and component parts, impacting manufacturing and distribution [271]. - The company is subject to various risks including demand and market acceptance for new and existing products, competitive pressures, and challenges in predicting customer preferences [270]. Strategic Initiatives - The company has undertaken strategic actions, including the sale of its Kidney Care business and the acquisition of Hillrom, to achieve long-term financial improvement goals [270]. - The company is focused on developing and integrating artificial intelligence and other emerging technologies into its products and services [271]. Tax and Credit Ratings - Effective income tax rate was 142% for Q3 2025 compared to 12% for Q3 2024, influenced by an increase in liabilities for uncertain tax positions [224]. - Moody's revised the company's senior debt credit rating outlook from stable to negative during the third quarter of 2025 [260].

Core Viewpoint - Investors in Baxter International, Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed systemic defects in the Novum LVP device that resulted in serious patient risks [2]. Summary by Sections Lawsuit Details - The lawsuit alleges that from February 23, 2022, to July 30, 2025, Baxter failed to disclose significant issues with the Novum LVP, including systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not adequately address them, leading to misleading positive statements about the company's operations and prospects [2]. Participation Information - Investors who suffered losses related to Baxter are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for December 15, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device, which reportedly suffered systemic defects leading to serious patient risks [4][6]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that caused malfunctions, including underinfusion and overinfusion, which posed risks of serious injury or death to patients [6]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm to patients [6]. - The company’s statements about the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading based on the undisclosed risks and defects [6]. Group 2: Impact on Stock and Legal Proceedings - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, which resulted in a 22.4% drop in stock price, closing at $21.76 [7]. - Investors who suffered losses exceeding $10,000 between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [4][9].

Core Viewpoint - Baxter International (BAX) was regarded as a strong player in the healthcare sector before the pandemic, with its stock trading at approximately 25 times the earnings per share at the end of 2019, indicating a significant premium valuation [1]. Group 1 - The stock performance of Baxter International prior to the pandemic was notable, reflecting investor confidence in its business model and growth potential [1].

Before the pandemic, Baxter International ( BAX ) was considered one of the better businesses in the health care space. At the end of 2019, BAX stock traded at about 25x that year's earnings per share, a significant premiumI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a small, tech-focused retail broke ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take existing Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device malfunctions, which have reportedly caused serious risks to patients [2][4]. Group 1: Allegations and Impact - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that led to malfunctions, including underinfusion and overinfusion, posing risks of serious injury or death to patients [4]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to a heightened risk of customers removing the Novum LVPs from service and pausing new sales [4]. - Following the announcement on July 31, 2025, regarding the voluntary pause of shipments and installations of the Novum LVP, Baxter's stock price fell by 22.4%, closing at $21.76 [5]. Group 2: Legal Proceedings - Investors who suffered losses exceeding $100,000 in Baxter between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Baxter is December 15, 2025 [2][6]. - Faruqi & Faruqi is also inviting anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to come forward [6].

CONTACT US HERE:https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form- 2/?id=174900&from=4 CLASS PERIOD: February 23, 2022 to July 30, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Baxter's recently launched product, the Novum LVP, suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-del ...

Core Insights - Baxter International Inc. has a market capitalization of $9.5 billion and specializes in medical products and therapies, focusing on renal care, medication delivery, and pharmaceuticals [1] Stock Performance - Over the past 52 weeks, Baxter's stock has decreased by 48.5%, significantly underperforming the S&P 500 Index, which gained 17.7% during the same period [2] - Year-to-date, Baxter's stock has fallen 36.7%, while the S&P 500 has risen by 16.3% [2] Sector Comparison - Baxter's shares have also underperformed compared to the Health Care Select Sector SPDR Fund, which saw a 2.6% drop over the past 52 weeks [3] Financial Performance - In Q3 2025, Baxter reported an adjusted EPS of $0.69, which was better than expected, but the stock plunged 14.5% due to revenue of $2.84 billion missing forecasts [4] - The company has cut its full-year adjusted EPS guidance to a range of $2.35 - $2.40 and reduced expected sales growth to 4% - 5% due to hurricane-related disruptions [4] Analyst Expectations - Analysts expect Baxter's adjusted EPS for the current fiscal year to grow by 24.9% year-over-year to $2.36 [5] - The consensus rating among 16 analysts covering the stock is a "Hold," with two "Strong Buy" ratings, 13 "Holds," and one "Moderate Sell" [5] Price Target Adjustments - Goldman Sachs has cut Baxter's price target to $22 while maintaining a "Neutral" rating [7] - The mean price target of $26.77 suggests a 44.9% premium to the current price, while the highest price target of $40 indicates a potential upside of 116.6% [7]